Company: MYSEW
Filing Date: 2025-11-26
Form Type: S-3
Source: 0001213900-25-115502
Chunk: 3

Company: Myseum, Inc.
Filing Date: 2025-11-26
Form: S-3
Chunk 3
---
 of
any securities to be offered, and the specific manner in which they may be offered, will be described in one or more supplements to this
prospectus. This prospectus may not be used to consummate sales of any of these securities unless it is accompanied by a prospectus supplement.
Before investing, you should carefully read this prospectus and any related prospectus supplement.

Our common stock presently
listed on The Nasdaq Capital Market under the symbol “MYSE.” On November 24, 2025, the last reported sale price of our common
stock was $1.93 per share. The applicable prospectus supplement will contain information, where applicable, as to any other listing on
The Nasdaq Capital Market or any securities market or other exchange of the securities, if any, covered by the prospectus supplement.
Prospective purchasers of our securities are urged to obtain current information as to the market prices of our securities, where applicable.

These securities may
be sold directly by us, through dealers or agents designated from time to time, to or through underwriters, dealers, or through a combination
of these methods on a continuous or delayed basis. See “Plan of Distribution” in this prospectus. We may also describe
the plan of distribution for any particular offering of our securities in a prospectus supplement. If any agents, underwriters or dealers
are involved in the sale of any securities in respect of which this prospectus is being delivered, we will disclose their names and the
nature of our arrangements with them in a prospectus supplement. The price to the public of such securities and the net proceeds we expect
to receive from any such sale will also be included in a prospectus supplement.

Investing in our securities involves various risks. See “Risk Factors” contained herein for more information on these risks. Additional risks will be described in the related prospectus supplements under the heading “Risk Factors.” You should review that section of the related prospectus supplements for a discussion of matters that investors in our securities should consider.

Neither the U.S. Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or passed upon the adequacy or accuracy of this prospectus or any accompanying prospectus supplement. Any representation to the contrary is a criminal offense.

<div align='center'>The date of this prospectus
is [______], 2025.

TABLE OF CONTENTS</div>

|                                         |     | Page |
| ABOUT THIS PROSPECTUS                   |     |   ii